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Epigenetic modifications serve as a means of intermediate gene expression control and 
nutritional inputs may modify methylation patterns in regulatory regions of genes.  Therefore, we 
proposed that folate availability affects adipocyte development and metabolism through impacting 
the one-carbon cycle and subsequent DNA methylation patterns.  Accordingly, we sought to 
determine if the methylation level of CpG islands could be influenced in adipocytes and if so, how 
this might affect gene expression in mature adipocytes.  We treated adipocytes with 0 to 0.9 
millimolar [mM] folate, the methyl donor S-adenosylmethionine (SAMe) and the methylation 
inhibitor, 5-aza-2-deoxycitidine (2-DC) during adipocyte differentiation and the maturation 
process. Lipogenesis was measured by accumulation of oil red O and lipolysis was quantified by a 
glycerol release assay. Methylated regions of adipocyte genomic DNA were evaluated using a 
methylation-specific antibody and hybridized against a Nimblegen whole genome CpG island array 
to identify targets for expression analysis. RNA was obtained and genes involved in adipocyte 
differentiation, one-carbon metabolism, lipogenesis and lipolysis were quantified using RT-PCR.    
We found that low folate levels or inhibition of DNA methylation by 2-DC decreased CpG 
methylation, thus increasing gene expression in some genes.  Surprisingly, SAMe similarly 
increased gene expression and decreased global CpG methylation. Low folate increased lipid 
accumulation and subsequent lipolysis.  Exposure to folate during the critical differentiation 
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Chapter 1 Introduction 
Obesity, defined as having a body mass index (BMI) exceeding 30 kg/m2, has become a global 
epidemic, significantly increasing morbidity and mortality associated with medical conditions such 
as Type II diabetes (T2D), hypertension, cardiovascular disease and some cancers (1).   The 
prevalence has nearly tripled for adolescence during the past two decades according to a report by 
the Office of the Surgeon General (2).  The report cites an obesigenic environment wherein an 
excess of calories are consumed with a concurrent decrease in caloric expenditure as the primary 
causal factor in the rapid climb of obesity rates.  However, genetic factors clearly contribute to the 
phenomenon as well as evidenced by adoption studies wherein adopted children’s adiposity and fat 
distribution is more similar to their biological parents than their adoptive parents (3).  Over the 
past decade, genome wide association studies have tried to link specific gene anomalies with 
obesity but, with a few exceptions such as gene mutations (ex. melanocortin 4 receptor deficiency), 
or imprinting disorders  (ex. Prader-Willi syndrome) and polymorphic genes (ex. peroxisome 
proliferative activated receptor-γ SNPs), an overwhelming direct link has yet to be made to explain 
differences in lipid storage and energy expenditure (3).   
As the primary depot for lipid storage in the body, adipose tissue was long thought to be merely 
a storage vessel for excess triglycerides, but it is now understood to influence chronic disease 
through release of cytokines which can increase chronic inflammation.  Adipocyte hypertrophy 
results in an increase in the release of inflammatory cytokines and a decrease in anti-inflammatory 
cytokines; thus, decreasing adipocyte size, while increasing adipocyte numbers may decrease the 
chronic disease risk associated with subclinical inflammation (4).  
Recent work with stem cells and pluripotent cells, including pre-adipocytes, has shown that 
nutrient and hormonal balance can effect cellular differentiation and may ultimately be directive for 
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deeming the cell type, a concept known as developmental plasticity (5).  This cellular flexibility may 
allow for sensing environmental conditions during cellular development in utero, but may be 
problematic when the external environmental conditions do not match those seen during initial 
development.  It has been proposed that nutritional mismatch may be a causative agent for future 
disease development (6).  The Dutch Hunger Winter during World War II yielded evidence that 
poor maternal nutrition resulted in increased incidence of obesity, CVD and diabetes in adult males.  
This study and others gave rise to the “Thrifty Phenotype Hypothesis” that proposes metabolic 
programming of the fetus during development in a nutrient poor environment in utero prepares the 
fetus for a post-natal environment that is similarly nutrient poor. However, when the post-natal 
environment is rich in nutrients, increased risk for obesity and metabolic syndrome may ensue (7). 
Recent data suggest that epigenetic changes appear to be involved in this environmental sensing of 
nutritional status.  Epigenetic changes involve changes to the genome structure that do not include 
DNA base pair differences, for example, DNA methylation of cytosine residues.    A critical 
component of DNA methylation is the ability to create S-adenosylmethionine (SAMe), the primary 
methyl donor in the body.  Dietary folate is involved in the creation SAMe through the one-carbon 
metabolism pathway.  Folate is converted to 5’ methyltetrahydrofolate which donates a single 
carbon to homocysteine to create methionine which in turn is necessary for the formation of SAMe.  
This research is based on the premise that deficiency in folate may affect DNA methylation 
and thus adipocyte development by causing hyperproliferation and increased lipogenesis.   
Epigenetic changes can also involve modification to histone proteins which are important in 
maintaining chromatin structure and packaging.  Non-coding small interfering RNAs can also have 
an epigenetic influence on gene expression.  Both of these mechanisms are responsible for 
providing rapid and fluid changes to the genome.  Longer-term effects can be supplied by 
methylation of cytosine residues in the DNA sequence context of CpG sites which are often located 
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in the promoter regions of genes.  Originally it was thought methylation of cytosine residues in the 
promoter region would reduce gene expression. It has subsequently been found, that methylation 
of cytosine residues can also serve to attract transcription factors to a promoter region and in some 
cases may actually increase gene expression.   One of the first examples of methylation affected 
gene expression was observed in Avy (viable yellow agouti) mice (8).  In this animal model, there is a 
transposable element inserted upstream of the transcriptional start site of the agouti gene.  This 
region contains CpG islands which can be methylated to varying degrees.  Phenotypic changes occur 
depending on the level of methylation of the CpG islands. When the CpG site is unmethylated, the 
agouti expression results in yellow obese mice.  As shown below, the phenotype switches to a dark 
brown, lean mouse with addition of methyl donor supplementation to the diet (folic acid, Vit. B12, 
choline and betaine) (9) .   The phenotype was linked to the degree of methylation in the CpG island 
upstream of the agouti gene. These results suggest nutrient intake has the potential to effect 
adipocyte development.   
  
Figure 1 a.  methylation status of IAP region effects coat color and Figure 1 b. mice exposed 
to folate diet are lean and brown (far right)(10). 
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Metabolic plasticity has been shown to depend on early nutritional status, with maternal diet 
influencing the phenotype and long-term disease potential in offspring (11-13). For example, 
feeding a protein restricted (PR) diet to rats during pregnancy was found to be associated with 
metabolic dysregulation in the offspring fed a high fat diet during the pubertal period.  While, 
supplementation of the mother’s PR diet with folic acid during pregnancy reduced metabolic 
deregulation in the offspring, supplementation of the offspring diet with high folate during the 
pubertal period, did not affect the phenotype or epigenotype induced by the PR diet (14). The 
researchers concluded the offspring phenotype was set prior to the juvenile-pubertal stage.  Human 
data supporting metabolic plasticity is exhibited in children born before and after maternal weight 
loss by bariatric surgery.  Children born after maternal weight loss have a lower risk for obesity 
than do their siblings born before maternal weight loss, an effect attributed to improved intra-
uterine environment (15-16).   
 Other studies indicate that the differentiation and lipid metabolism of adipocytes may depend 
on the level of methylation occurring in the upstream promoter region of genes.  For example, in 
3T3-L1 mouse pre-adipocytes there are two CpG sites which are highly methylated in the promoter 
region of the GLUT4 gene, which become highly demethylated in mature adipocytes (17).  
Furthermore, a change in methylation status is reflected in the development of adipocytes from 
stem cells carried through to senescence (18).  Beyond genes directly involved in adipocyte 
development and metabolism, other genes have been found to have epigenetic impacts on the 
genome.  For example, the obesity associated FTO gene could have a role in nucleic acid 
demethylation (19).  
Several key compounds are necessary for the manufacturing of S-adenosyl methionine (SAMe), 
the primary methyl donor.  Choline, methionine, betaine, vitamin B12 and folate all play a role in 
one-carbon metabolism and the cycling between SAMe and homocysteine.  This is a complex 
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pathway, and the most research to date has been on folate supplementation when a correlation was 
made between increased folate consumption and a decrease in the incidence of neural tube defects 
(NTDs).  Although a direct cause for the reduction in NTD has not been determined, in 1992, the US 
Public Health Services and Institute of Medicine (IOM) recommended that all women of 
childbearing age should consume a supplement containing 400 µg of folic acid daily to prevent 
NTDs.  Unfortunately, compliance was found to be low (~ 29%), therefore, in 1996, the Food and 
Drug Administration (FDA) mandated that by 1998 all cereal grain products sold in the US must be 
fortified with folic acid (140 µg folic acid per 100 gm of grain).  According to 2004 data, NTDs have 
decreased an estimated 30% since the fortification program began (20).  Yet, the long-term 
implications of folic acid supplementation are not yet known.  Folate sufficiency has been 
associated with a lower risk of some cancers such as esophageal, stomach and ovarian cancer.  
However, it has also been suggested that excess folate may promote tumor initiation (21).  It is most 
likely that there is a U-shaped response from folate where too much or too little is problematic. 
Therefore, more work is necessary to understand the ramifications of folate inadequacy and 
excesses, particularly during early cellular development and maturation.  To that end, this research 
is focused on the effect of folate availability during differentiation and maturation on adipocyte 
lipid storage and release in light of DNA methylation.  It is hoped we might gain a better 




Chapter 2 Literature Review 
Background 
Obesity is a disease state resulting from an imbalance between energy intake and energy 
expenditure. Excess calories create a positive energy balance with the excess energy stored in the 
form of triglycerides in adipose tissue and carbohydrates in the form of glycogen in muscle tissue.  
This increase in adiposity can contribute to hypertension, dyslipidemia, Type 2 diabetes, coronary 
heart disease, stroke, gallbladder disease, osteoarthritis, sleep apnea and respiratory problems, and 
increased risk of some types of cancer (breast, endometrial and colon) (22). In the last few decades, 
the prevalence of obesity in the United States, (defined in adults as a body mass index greater than 
30 kg/m2) has increased from 15% to nearly 33% in adults age 20-74 (23). The number of 
overweight children ages 2-19 has increased from 5% to 19% (23-29).  One of the national health 
objectives put forth in Healthy People 2010 was to reduce the prevalence of overweight individuals 
to 15% by 2010 (30). Unfortunately, we fell far short of the goal as data from 2008 estimated adult 
obesity at 34% and childhood obesity at 17% (31). The results show that Americans are not 
meeting the recommended intake for fruits, vegetable and whole grains.  For example, the target for 
dark green or orange vegetables was 50% of total daily caloric intake, but consumption has been 
maintained since 1994 at a dismal 4%.  Whole grain intake has remained similarly low at an 
average of 3%.  In addition, approximately 80% of Americans do not get the recommended 
amounts of physical activity. New guidelines set forth in Healthy People 2020 include a 10% 
reduction in obesity levels in both adults and children.  The guidelines include recommendations 
for increasing access to healthy foods and decreasing access to high fat, high caloric foods for 
children.  There are specific targets for increasing fruits and vegetables, whole grains, calcium and 
iron consumption, but no targets set for folate consumption (31).   In order to accomplish a 
reduction in obesity, we must gain a better understanding of the causes of obesity. 
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There are many contributing factors to the obesity epidemic.  The first factor is the energy 
imbalance created from consuming more dietary energy than is expended in physical activity.  The 
average number of calories consumed per day has increased with a concurrent decline in caloric 
expenditure over the past few decades (32).  Genetics also play a significant role contributing an 
estimated 30% to 70% of heritability for obesity risk (1).  However, genome wide association 
studies looking at single nucleotide polymorphisms (SNPs) and other gene mutations have failed to 
find many strong genetic links.  A few genes have been associated with increased risk for obesity.  
For example, variants of the FTO gene which encodes the fat mass and obesity associated protein 
correlates with obesity risk (19).  The fidelity of DNA replication is high and typically has a very low 
mutation rates, approximately 1 mistake per 100 to 1000 base pairs (33-34). Therefore changes in 
DNA at the gene sequence level are unlikely to be the cause for the rapid increase in obesity during 
the last few decades.  During this time, the prevalence of obesity in offspring of obese parents has 
increased dramatically as well, possibly showing a non-polymorphic genetic link.   With this in 
mind, what could be driving genetic changes? 
Epigenetics and DNA Methylation 
It has been recently shown that modifications to the bases of DNA sequence can affect the 
regulation and expression of genes (35).  Furthermore, these modifications can be either inherited 
by offspring or changed over the course of one’s lifetime.  The modifications are known as 
epigenetic or “above” the genetic code changes.  There are three categories of epigenetic changes; 
1) methylation of nucleic acid residues, for example, methylation of cytosines in the CpG sequence 
context, 2) chromatin modification by histones via acetylation, methylation, phosphorylation, 
ubiquitylation, or sumoylation and 3) non-coding RNAs (36) .  While any of these three epigenetic 
changes could be responsible for an increase in obesity rates, methylation of cytosine residues has 
been implicated in having the potential for successful modulation through nutritional interventions 
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(37-40).  Furthermore, it has been suggested that epigenetic regulation of pre-adipocytes occurs on 
multiple levels and is responsible for determining the rate and fate of the differentiation process 
(41).   
One of the best understood mechanisms for epigenetic change is alteration in DNA 
methylation patterns created by the addition or subtraction of a methyl group to the 5-carbon 
position of the cytosine residues in the CpG dinucleotide. Methylation of CpG residues in the 
regulatory regions of genes typically acts to suppress expression of a gene.  Conversely, 
hypomethylation in regulatory regions may increase expression of a gene.   DNA methylation is 
important for silencing imprinted genes, X-chromosome inactivation and silencing 
retrotransposons.  Once a cell has determined a specific DNA methylation pattern, the methylated 
sites are inherited by daughter cells during cell division.  In this manner, quickly dividing cell lines 
are more prone to impacts caused from changes to their methylation patterns.   Methylation of DNA 
is largely established during embryogenesis and early in post-natal life by DNA methyltransferases 
(Dnmts).  Shortly following fertilization, maternal and paternal DNA is demethylated followed by 
global methylation just prior to blastocyst implantation by two de novo methyltransferases, Dnmt3a 
and Dnmt3b. During this time, approximately 70% of CpGs are methylated with lineage specific 
methylation of tissue specific genes occurring (42).  Methylation continues throughout prenatal 
development and into early post-natal life.  It is generally conserved throughout life with the 
exception of exposure to environmental perturbations and some loss of methylation during aging. 
For example, the gene encoding the enzyme phosphoenolpyruvate carboxykinase (PEPCK) is 
methylated during early embryogenesis, but undergoes progressive demethylation during 
development.  Dnmt1 serves as the maintenance DNA methyltransferase and copies 
hemimethylated DNA marks.  It is recruited to the DNA by histone deacetylase 1 and 2, Suv39 and 
E2H2, suggesting that chromatin structure plays a role in determining methylation patterns and 
vice versa (43).       
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DNA methyltransferases deliver methyl groups from the primary methyl donor S-
adenosylmethionine (SAMe) to the cytosine residues, reducing SAMe to S-adenosylhomocysteine 
(SAH) in the process, which is in turn converted to homocysteine.   5’ Methyl tetrahydrofolate 
combines with homocysteine in the presence of B12, to form methionine, which is in turn used to 
generate S-adenosylmethionine, thus completing the cycle.  Central to the one carbon pathway is 
the availability of the co-factors, in particular, folic acid derived from dietary sources.  Folic acid is 
converted to tetra-hydro folate (THF) by dehydrotetrahydrofolate reductase (DHFR).  Then THF is 
reduced to 5’,10’-methylene tetrahydrofolate, which acts as a methyl donor for the enzyme 
thymidylate synthase which converts deoxyuridine monophosphate to thymidine monophosphate.  
Folate in the form of 10-formyl tetrahydrofolate is also necessary for purine biosynthesis.  
Alternatively, 5’10’-methylene THF can be converted to 5’ methyl THF by methylene 
tetrahydrofolate reductase (MTHFR) in the presence of niacin and riboflavin.  Polymorphisms in the 
MTHFR gene (677C>T) can reduce the ability of this enzyme to function effectively and may shunt 
folate in the direction of DNA and RNA biosynthesis versus SAMe generation, thus reducing global 
DNA methylation (44-46).  Therefore, it is clear that perturbations in the one-carbon cycle have the 
ability to impact not only DNA and RNA biosynthesis, but also DNA methylation.   
Experimental Models of Epigenetically Induced Obesity 
Epigenetic research has shown that aberrant DNA methylation patterns are present in many 
disease states such as cancer and other genetic diseases.   Early life environment is critical to the 
creation of DNA methylation patterns. The first evidence of the impact of nutrient deficiency on 
imprinted gene expression was from mouse embryos grown in Whitten’s media with no amino acid 
supplementation that exhibited biallelic expression of imprinted gene H19,  while embryos given 
amino acid supplementation showed monoallelic expression of H19 (47).  Similarly, human 
embryos cultured by in vitro fertilization (IVF) have a higher risk of developing Angelman’s 
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Syndrome and Beckwith Weideman Syndrome by decreased methylation of the normally imprinted 
genes UBE3a, H19 and IGF2 (48-49).   In 1996, Insulin growth factor 2 (IGF2) was shown to be 
differentially methylated in human populations and that differential “imprinting” was responsible 
for somatic growth (50).  Computational studies suggest that perhaps 150 or more human genes 
may be capable of being modified in such a manner, including the insulin growth factor 2 receptor 
(IGF2R) and the transcriptional binding site, CCAAT-enhancer-binding protein (C/EBP), which has 
strong implications for possible impacts of aberrant methylation on obesity (51). 
In animal studies, rat dams fed protein restricted (PR) diets had pups with increased cardio-
metabolic disease.  The pups had increased glucocorticoid receptor and PEPCK expression with a 
concurrent increase in gluconeogenesis.  They also had decreased expression of 11β- 
hydroxysteroid dehydrogenease Type II (14, 52-54). The rat pups had higher levels of tri-acyl 
glycerol and non-esterified fatty acids in their blood stream.  Furthermore, it was shown that genes 
involved in lipid homeostasis were affected in the rat pups with increased expression of acetyl co-A 
carboxylase and fatty acid synthase.  In the liver, PPARα and it’s target, acyl CoA oxidase, were 
increased, while PPARγ in adipose tissue had reduced expression.   The changes in gene expression 
were linked to changes in the level of gene promoter methylation levels.   The pregnant rats fed a 
PR diet had increased blood levels of homocysteine, which negatively regulates Dnmt1.    Folic acid 
has been shown to increase Dnmt1 levels, thus differences in the nutrients involved in the one-
carbon metabolic pathway provide a link between maternal diet and epigenetic regulation of genes.  
Researchers fed various constituents of the one-carbon metabolic pathway (folate, choline, 
and B12) to Avy (variable yellow agouti) mice to study the potential for perturbations in the 
pathway to effect phenotype (8). There is a transposable element inserted upstream of the 
transcriptional start site of the agouti gene.  This region contains CpG islands which can be 
methylated to varying degrees (Figure 1A) (7).  They showed that phenotypic changes occur 
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depending on the level of methylation of the CpG islands. When the CpG site is unmethylated, the 
agouti expression results in yellow obese mice.  The phenotype switches to a dark brown, lean 
mouse with addition of methyl donor supplementation to the diet (Figure 1B) (7).  Surprisingly, 
these phenotypic traits can be passed on trans-generationally through at least three subsequent 
generations (40).  
Folate Availability and Propensity for Obesity: A possible link 
Data acquired from a period known as the Dutch Hunger Winter, a famine which occurred in 
German occupied Netherlands during 1944-1945, revealed the importance of maternal diet on 
adult children’s health.  The average caloric intake dropped to an average of 400 calories per day. 
Children conceived during this time had increased risk of developing schizophrenia and heart 
disease as adults.  Furthermore, the timing of exposure to low caloric intake was shown to impact 
risk.  Fetuses exposed to the famine during the first trimester had increased risk relative to those 
fetuses exposed to low caloric intake after the first trimester.  Children conceived during the famine 
showed decreased methylation of imprinted regions of IGF2 and as adults were more at risk for 
developing obesity (55).    
Godfrey et al found that the level of promoter methylation at birth of several genes including, 
retinoid X receptor alpha (RXRA) and endothelial nitric oxide synthase (eNOS) was associated with 
a child’s fat mass at age 9 years of age (56).  Since folate is critical to one carbon metabolism and 
production of S-adenosylmethionine, it is possible that low folate exposure in utero, could affect 
promoter methylation and ultimately lead to increased risk for obesity.  The Thrifty Phenotype 
Hypothesis suggests a nutrient deficient diet in utero sets up a person for increased risk to obesity 
when a high nutrient diet is encountered post-natally, because the genes have been “programmed” 
for a nutrient deficient environment (57).   Tamashiro et al, suggest there is a U-shaped relationship 
between birth weight and adult fat mass, such that low birth weight or large birth weight 
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predisposes one to increased fat mass as children and adults (7).  Despite having a positive energy 
balance and food intake, obesity has been characterized by micronutrient deficiency (58). Han et al 
found that obese subjects in a South Korean population had significantly lower serum folate levels 
than did underweight subjects.   Furthermore, in this population those women with high pre-
pregnancy BMI had increased risk for pre-term delivery and children born with low birth weight 
(59).  Stern et al found differences in folic acid absorption and metabolism between obese women 
and non-obese woman of child bearing years. They concluded that women with a BMI >30 kg/m2   
require an additional  350 micrograms of folic acid per day to achieve a folate status similar to 
women in the lowest BMI category.   
In 1998, the U.S. Federal Drug Administration began requiring enrichment of all cereal grain 
products with folic acid, after it was determined that serum folate levels >15.9nmol/L and red 
blood cell  >906 nmol/L are needed to reduce neural tube defects.  Analysis of National Health 
Nutrition Examination Survey (NHANES) data acquired from 1988 to 2004 revealed a statistically 
significant increase in the survey population’s serum folate levels when comparing pre-folate 
fortification (1988-1994) to post-folate fortification (2003-2004).  Mean serum folate levels 
increased two-fold from 11.4 nmol/L to 26.9 nmol/L and the erythrocyte folate concentration 
increased from 375 nmol/L to 590 nmol/L(60).  Dietrich et al estimate the prevalence of low serum 
folate (<7 nmol/L) has decreased significantly since the introduction of fortification,  from 
approximately 25% to around 1% (51). It is clear that a segment of the U.S. population prior to 
1998 had sub-optimal levels of folate and this could have affected the promoter methylation of their 
genes, as well as that of their offspring.  Alternatively, folic acid may in itself improve lipolysis as 
shown by Lam et al in studies with obese/diabetic mice given folic acid supplementation.   They 
found that folic acid did not increase basal level lipolysis, but enhanced β-adrenergic receptor 
mediated lipolysis when adrenaline was administered.   Activation of β-adrenergic receptors 
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induces phosphorylation of hormone sensitive lipase and stimulates lipolysis through cAMP-PKA-
dependent signaling pathway (61). 
The process by which the body maintains a constant predefined range of body weight has been 
termed the Adipostat by Patrick Tounian (62).  He suggests one must be constitutionally 
predisposed to obesity before an obesegenic environment causes one to become obese.  He cites 
studies in which obese children’s bodies seem to actively resist attempts at weight loss by 
stimulating appetite and reducing energy expenditure in order to maintain body weight.  Could 
folate be a mechanism by which the adipostat is set and controlled? 
Adipose Tissue Composition 
Adipose tissue was long thought to merely a storage site for excess energy.  Now it is recognized 
as an endocrine organ excreting cytokines active in immune function, leptin which helps to control 
appetite, estrogen and resistin (63).  Adipose tissue comes in two forms, white adipose tissue 
(WAT) and brown adipose tissue (BAT).  While WAT serves as an energy storage vessel, BAT helps 
to disperse energy when necessary (64). White adipose tissue is distributed throughout the body 
and around organs, but typically is compartmentalized into subcutaneous or visceral regions.  Of 
the two types, visceral fat has a higher association with metabolic diseases and diabetes.   Visceral 
fat adipocytes are typically smaller in size than those in subcutaneous fat and the cells contain less 
lipid.  Despite being smaller, visceral fat cells have a faster lipolytic rate and secrete more cytokines 
(65). 
Two factors determine the total fat mass in humans, 1) total adipocyte numbers and 2) 
adipocyte size.  Research has shown that the total number of fat cells remains constant in adulthood 
in both lean and obese individuals, even after weight loss (66).  The number (hyperplasia) of fat 
cells one will have seems to be set in early childhood or adolescence.  The ability of adipocytes to 
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increase in size (hypertrophy) remains throughout adulthood and is ultimately responsible for total 
fat mass (66).  Each year an estimated 10% of adipocytes will die and be replaced with new cells 
(66).   Since mature adipocytes do not usually divide, new adipocytes are derived from a pool of 
pre-adipocytes.   
Adipocyte Determination and Differentiation 
There are two main steps in the development of mature adipocytes from mesenchymal stem 
cells (MSCs).  MSCs have the capacity to differentiate into myotubes, adipocytes, chondrocytes or 
osteocytes.  Determination is the first step wherein MSCs are pushed onto the adipocyte path by 
becoming a pre-adipocyte cell, and the second step is differentiation.  A complex cascade of events 
occurs during differentiation and terminal differentiation involving  selective silencing and 
activation of genes at specific time-points via binding of  transcription factors, histone and 
acetylation modifications as well as phosphorylation activation and deactivation events and has 
been reviewed extensively (67), (68), (69), (41).    
Commitment of the fibroblastic MSC to the pre-adipocyte path in vitro involves bone 
morphogenetic proteins (BMPs) such as Bmp4 which has been show to stimulate the differentiation 
of MSC into adipocytes.  The cells move from a fibroblastic shape to a more spherical morphology 
created by changes in extracellular matrix and cytoskeletal components as expression of adipogenic 
transcription factors increases including CCAAT/Enhancer binding protein- α (C/EBP α) and 
peroxisome proliferator-activated receptor-γ (PPARγ).   
In the 3T3L1 murine adipocyte cell line, the differentiation process can be divided into 3 stages; 
1) growth arrest 2) mitotic clonal expansion and 3) terminal differentiation.  The first stage of the 
differentiation process occurs 48 hours after cells have exited the cell cycle.  This is often attributed 
to, but necessarily due to, contact inhibition.   Primary rat pre-adipocytes plated at low density in 
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serum-free media have been shown to differentiate without contact inhibition  (67).  Exit from the 
cell cycle has been linked to changes in extracellular matrix (ECM) proteins.  After growth arrest, 
the addition of insulin, isobutylmethylxanthine (IBMX) and dexamethasone (DEX) will induce 
adipocytes to differentiate.   This cocktail stimulates the insulin/IGF-1, c-AMP and glucocorticoid 
signaling pathways.   The transcription factor families CCAT/enhancer binding proteins (C/EBPβ 
and C/EBPδ) levels begin to increase within 1 to 4 hours after stimulation. The cells will reenter the 
cell cycle and begin mitotic clonal expansion the second step in differentiation.  C/EBPβ becomes 
hyperphosphorylated through the action of MAPK and SK3β.  This in turn stimulates the 
transcription of C/EPBα, peroxisome proliferator activated receptor (PPAR)-γ, adipocyte 
determination and differentiation factor (ADD-1), and the sterol regulatory element binding protein 
(SREBP)1c.  After day 2, C/EBPα begins to accumulate and is phosphorylated by Cyclin D-3/CDK 
complex.  This causes an inhibitory effect on the cells and they are prompted to exit the cell cycle.  
PPARγ up regulates the expression of GOS2 and the cyclin dependent kinase inhibitor, p21, further 
directing the cell to exit the cell cycle.  PPARγ also down regulates the serine-threonine 
phosphatase, PP2A, which inactivates the E2F-DP complex by dephosphorylation.    By day 7 post-
differentiation, most adipocytes have fully matured.  The enzymes involved in lipid metabolism and 
glucose uptake as well as the adipocyte production of cytokines and hormones are fully activated 
(67). 
The adipocyte differentiation process is accompanied by changes in genome-wide DNA 
methylation status (70). Treatment of 3T3-L1s with the DNA methyltransferase inhibitor, 5-aza-
2’deoxycytidine, at a 1 micromolar concentration inhibited differentiation and lipid accumulation.  
However, the magnitude of the effect was dependent on the timing of exposure to the inhibitor.  For 
example, pre-adipocyte (-2 to 0 days) exposure to the inhibitor decreased accumulation of lipid by 
40% relative to a no treatment control. While exposure to the inhibitor during the late stage of 
differentiation (0 to 2 days) did not affect lipid accumulation.  These results suggest that DNA 
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methylation is involved in the differentiation process of 3T3-L1s. Furthermore, evaluation of both 
CpG and non-CpG regions upstream, within or downstream of exonic regions, found that 
methylation levels changed depending on whether the adipocyte was growing, confluent, post-
confluent or mature.   This non-static nature of DNA methylation was shown for several genes 
including Lep and Glut4.   The authors concluded that some DNA methylation changes are transient 
events, which are dynamic and not static, and this is a common mechanism in differentiation of 
somatic tissues and not restricted to early embryo development (70). 
Adipocytes and Energy Metabolism 
Adipocytes are the primary storage site for excess energy in the form of triglycerides.   The 
process of lipogenesis begins as free fatty acids (FFA) are liberated from lipoprotein-triglycerides 
by lipoprotein lipase.  Upon entering the cell, the FFA are esterified to a glycerol-3-phophate and 
stored as lipid droplets.    Triglycerides can also be synthesized by de novo lipogenesis from acetyl-
CoA by the enzymes fatty acid synthase (FASN) and acyl-CoA- carboxylase (ACC). Although in whole 
body system de novo lipogenesis is thought to play a minor role in triglyceride storage (71). 
When adipocytes are in a fasted state, the triglyceride stores are released as FFA in the process 
called lipolysis.  This process may use three different lipases to cleave the FFA from it’s glycerol 
backbone: adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL) and monoglyceride 
lipase (MGL).  ATGL typically cleaves triglycerides and HSL prefers diglycerides.   Catecholamines 
can stimulate lipolysis by activating the β1 and β2 adrenergic receptors.  This stimulated the G 
receptor proteins to activate adenylate cyclase, which in turn causes an increase in c-AMP.  This 
causes a downstream activation of cAMP-dependent protein kinase-A (PKA) which phosphorylates 
and activates enzymes such as HSL.  The most potent inhibitors of lipolysis are insulin and IGF.  
They interact with the insulin signaling pathway to activate 3-phosphoinositide-dependent protein 
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kinase (PDK1) and protein kinase C (PKC).  The pathway ultimately leads to degradation of cAMP 
and PKA activity (72). 
Role of Adipocytes in Development of Obesity and Metabolic Diseases 
White adipose tissue has been shown to play a major role in the development of diseases 
through secretion of adipocytokines, hormones and free fatty acids (FFAs).  Adipocytes are the 
major storage depot for triglycerides in the body and disturbances in lipid turnover and FFA 
mobilization is associated with obesity and metabolic disease (73).  Increased triglyceride 
breakdown is associated with obesity.  Excess white adipose tissue is also associated with 
decreased catecholamine stimulated lipolysis.  People with the same fat mass can vary substantially 
in the number of fat cells they possess.   Adipose tissue hypertrophy, characterized by a few very 
large fat cells, as opposed to hypercellularity which is characterized by a large number of cells, is a 
risk factor for metabolic disorders.  Of note, not all obese individuals develop obesity related 
disorders because they are able to maintain normal adipose tissue function (73).  There may be a 
genetic predisposition to fat cell phenotype, small cell type as in visceral tissues or larger cell type 
found in subcutaneous fat, and this predisposition may lie in the methylation status of the cells.  
Although many studies have suggested a correlation between methyl donor availability to effect 
DNA methylation and subsequent gene expression, direct studies in adipocytes to assess the impact 
of either limiting folate or providing excess folate on adipocyte lipid metabolism have yet to be 
done.  Furthermore, the effects of folate on differentiation versus post-differentiation lipid 
metabolism have not yet been studied.  Therefore we sought to add to the body of knowledge 
through designing experiments that would assess the ability of folate to effect DNA methylation and 
to understand if timing of the exposure ultimately makes a difference in the ability of the adipocyte 
to store and release lipids. 
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Chapter 3 Experimental Investigations 
To be submitted to the Journal of Nutrition 
Folate Levels During 3T3L1 Adipocyte Differentiation Have Sustained Impact on Lipogenesis and 
Lipolysis1 
Julia S. Gouffon 2,3, Megan E. Johnstone2, Michael B. Zemel2,3 
2 Department of Nutrition, 3Department of Comparative and Experimental Medicine, University of 
Tennessee, Knoxville, Tennessee, 37996 
Abbreviations used: Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), S-adenosylmethionine 
(SAMe), DNA methyltransferase 1 (Dnmt1), fatty acid synthase (Fasn), folate receptor 1 (Folr1),  
glucose transporter 4 (Glut4), hormone sensitive lipase (Lipe), leptin (Lep), 
methylenetetrahydrofolate reductase (Mthfr),  peroxisome proliferation activated receptor gamma 
(Pparγ), Pparγ coactivator 1 alpha (Pgc-1α), Hank’s Balanced Salt Solution (HBSS), Dulbecco’s 
Modified Medium (DMEM) 
Abstract 
Background/Aim: Epigenetic modifications serve as a means of intermediate gene expression 
control, and nutritional inputs may modify methylation patterns in regulatory regions of genes.  
Therefore, we proposed that specific nutrient availability of folate would affect adipocyte 
development and metabolism through impacting the one-carbon cycle and subsequent DNA 
methylation patterns.  Accordingly, we sought to determine if the methylation level of CpG islands 
could be influenced in adipocytes and if so, how this might affect gene signaling in mature 
adipocytes.  Methods: We treated adipocytes with 0 to 0.9 mM folate, the methyl donor S-
adenosylmethionine (SAMe) or a methylation inhibitor, 5-aza-2-deoxycitidine (Decitibine) during 
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adipocyte differentiation and the maturation process. Lipogenesis was measured by accumulation 
of oil red O and lipolysis was quantified by a glycerol release assay.  RNA was obtained and genes 
involved in adipocyte differentiation, one-carbon metabolism, lipogenesis and lipolysis were 
quantified using RT-PCR.  Methylated regions of adipocyte genomic DNA were evaluated using a 
methylation-specific antibody and hybridized against a Nimblegen whole genome CpG island array.  
Results:  Differentiation under folate depleted conditions increased lipid accumulation and 
enhanced lipolysis driven by increased expression of fatty acid synthase (Fasn), glucose transporter 
4 (Glut 4) and hormone sensitive lipase (Lipe). Exposure to increased levels of folate or SAMe post-
differentiation enhanced this effect.  Adipocytes differentiated under high folate levels had lower 
levels of leptin (Lep) under low folate maturation conditions than adipocytes differentiated under 
standard conditions.  Adipocytes differentiated under standard conditions exposed during 
maturation to depleted folate, decitibine or SAMe had decreased global CpG methylation relative to 
standard conditions including the promoter regions of Fasn, Glut 4, Lipe and Lep.  Conclusions: 
Promoter methylation in key metabolic regulatory genes was impacted by exposure to folate 
deficient conditions resulting in increased lipogenesis and lipolysis.   The level of folate exposure 
during adipocyte differentiation had greater impact on lipolysis and lipogenesis than did folate 
exposure during maturation.   
Introduction 
Recent work with stem cells and pluripotent cells, including adipocytes, has shown that 
nutrient and hormonal balance can affect cellular differentiation and ultimately be directive for 
deeming the cell type, a concept known as developmental plasticity(74). This cellular flexibility may 
allow for sensing environmental conditions during cellular development in utero, but may be 
problematic when the external environmental conditions do not match those seen during initial 
development.  It has been proposed that nutritional mismatch may be a causative agent for future 
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disease development (6).  The Dutch Hunger Winter during World War II yielded evidence that 
poor maternal nutrition resulted in increased incidence of obesity, CVD and diabetes in adult males.  
This study and others gave rise to the “Thrifty Phenotype Hypothesis” that proposes metabolic 
programming of the fetus during development in a nutrient poor in utero environment prepares for 
a post-natal environment that is similarly nutrient poor, however, when the post natal environment 
is rich in nutrients, metabolic syndrome ensues (7).  Recent data suggest that epigenetic changes 
appear to be involved in this environmental sensing of nutritional status. 
Metabolic plasticity has been shown to depend on early nutritional status with maternal diet, 
influencing the phenotype and long-term disease potential of offspring (11-13). The strongest 
human data supporting this hypothesis are from children born before and after maternal weight 
loss by bariatric surgery: children born after maternal weight loss have a lower risk for obesity than 
do their siblings born before maternal weight loss, an effect attributed to improved intra-uterine 
environment (15-16).   
Other studies indicate that the differentiation and lipid metabolism of adipocytes may depend 
on the level of methylation occurring in the upstream promoter region of key regulatory genes.  For 
example, 3T3-L1 mouse preadipocytes exhibit varying levels of methylation in the promoter region 
of the Glut4 gene during differentiation into mature adipocytes (17). Furthermore, a change in 
methylation status is reflected in the development of adipocytes from stem cells carried through to 
senescence (18).  Similar mechanism may be operative in adipocyte differentiation, and several 
metabolic genes could be affected by the amount of methyl donors in the diet during critical 
developmental stages.   
Several key compounds are necessary for the manufacturing the primary methyl donor in the 
body, S-adenosyl methionine (SAMe).  Choline, methionine, vitamin B12 and folate play a role in 
one-carbon metabolism and the cycling between SAMe and homocysteine.  In 1996, the U.S. 
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government implemented fortification of cereal grains with folic acid (140 µg folic acid per 100 gm 
of grain) (75).   Long-term implication or impacts of folic acid supplementation are not yet known.   
Since folate is involved in one-carbon cycling and a critical component for DNA methylation 
reactions, we sought to understand how the addition of folate might affect adipocytes through 
changing the methylation of CpG residues in the promoter regions of genes involved in lipolysis and 
lipogenesis. We proposed that CpG methylation status affects the transcription of metabolic genes; 
thus increasing folate levels would increase methylation of lipid metabolism regulatory genes 
thereby decreasing overall lipid accumulation in adipocytes.  Conversely, decreasing folate levels 
would decrease methylation, thereby increasing lipid storage.  
To test this hypothesis, we differentiated pre-adipocytes under folate depleted, standard folate 
and high folate conditions.  The adipocytes were matured under folate depleted, standard folate, 
high folate, superphysiological levels of folate, SAMe or 5-aza-2-deoxycitidine.  After one week of 
treatment, the cells were assayed for total lipid storage and lipid release.  RNA was acquired to 
measure gene expression levels and DNA promoter methylation was assayed using methylation 
microarray analysis (MIRA) (76).  We sought to determine if epigenetic methylation patterns either 
proximal or distal to promoter regions of metabolic gene involved in fatty acid oxidation, lipolysis, 
lipogenesis, glycolysis, and gluconeogenesis are set during the differentiation process of adipocytes 
or if they can be manipulated after differentiation in mature adipocytes.    
Materials and Methods 
Experimental Design 
Adipocytes were differentiated under one of 3 conditions: 1) folate depleted, whereby the only 
folate available was that which was stored during colony expansion and trace amounts from fetal 
bovine serum, 2) standard Dulbecco’s Modified Eagle Medium (DMEM) containing 9 µM folate, and 
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3) high folate conditions, DMEM supplemented with additional folate to a total concentration of 90 
µM folate.   Following differentiation each group was subdivided into six post-differentiation 
treatments. The first three treatments consisted of the aforementioned groups:  1) folate depleted, 
2) standard DMEM, 3) high folate as well as 4) supraphysiological folate containing 900 µM folate, 
5) 2 µM decitabine and 6) 100 µM S-adenosylmethionine. Small amounts of amendment stocks 
were aliquoted into dark storage tubes and stored at -20°C to prevent freeze/thawing and potential 
degradation of amendments.    Cells were treated every other day for one week post-differentiation 
with media made with freshly thawed amendments.  The experimental design overview is show in 
Figure 2  below. 
Figure 2 Experimental Design 
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Adipocyte Growth Conditions 
Early passage number (<5) murine 3T3-L1 preadipocytes (ATCC # CL-173) were expanded in 
Dulbecco’s Modified Eagle Medium (DMEM containing 4 mg/L Folic Acid) according to the standard 
ATCC protocol.  Preadipocytes were harvested after removing DMEM and washing with Hanks 
Balanced Salts Solution (HBSS) and trypsinization.  After centrifugation to remove HBSS and 
trypsin, cells were resuspended in DMEM and equal cell numbers (verified by hemocytometry 
counts) were transferred into 24-well plates.  Once cells were confluent, the DMEM was removed 
and cells were washed with HBSS.  One of 3 media types was placed over the cells; 1) folate reduced 
DMEM, 2) standard DMEM (folate free base with 4mg/L folate added and 10% FBS), 3) folate excess 
DMEM (folate free base with 40 mg/L folate added and 10% FBS).  Cells were acclimated to the new 
media for 1 day before addition of treatment media consisting of 6 types; 1) folate free DMEM with 
10% FBS , 2) Standard DMEM 9 uM Folate, 3) folate excess DMEM 90 uM Folate, 4) 
supraphysiological folate DMEM 900 uM Folate 5) 100 µM S-adenosylmethionine (SAMe) in a folate 
free base with 10% FBS, 6) 2 µM 5-aza-2-deoxycytidine (2DC) in a folate free base with 10% FBS.   
Treatment media was changed every 2 days with folate, SAMe and 2DC additions made to base 
media from freezer stocks just prior to feeding cells to ensure limited degradation of compounds. 
Cells were treated for seven days post differentiation to gather data during a transitional time, i.e. 
cells were not fully matured or static in lipid acquisition.  
Triglyceride accumulation 
On day seven post-differentiation, adipocytes were washed with 1X PBS and formalin fixed.  A 
solution of Oil Red O was added to the cells and allowed to stain the cells, followed by a wash with 
water (4 x) to remove any unbound stain.  Cells were imaged using a microscope and documented 
by photography.  Addition of 100% isopropanol eluted the Oil Red O from the cells.  The optical 
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density of 200 ul aliquots was determined at a wavelength of 540 nm using a Promega GloMax® 
plate reader (Promega Corp., Madison, WI. USA).   
Lipolysis 
Lipolysis (lipid release) was determined by a glycerol release assay (77).  On day seven, cell 
media was changed four hours prior to the start of the glycerol release assay to ensure that cells 
were not in a starved state prior to induction of the assay. A series of glycerol standards ranging 
from 0 to 1 mM was prepared in KRB/BSA buffer. Samples or standards were added to reaction 
mixtures (1:4 volumes) consisting of hydrazine buffer (Sigma-Aldrich), β-nicotinamide-adenine 
dinucleotide (Sigma-Aldrich) and glycerol dehydrogenase (Sigma-Aldrich). The NADH produced 
was measured using a Promega GloMax® plate reader (Promega Corp., Madison, WI. USA) and 
compared to the standard glycerol curve.  Lipolysis data was normalized to cellular DNA content 
because experiments showed treatments affected cell size, thus protein level (data not shown). 
CyQUANT Cellular Proliferation Assay 
DNA content was measured per directed by the CyQUANT assay (Life Technologies, Grand 
Island, NY, USA).  Cells were lysed in CyQuant GR dye/cell lysis buffer and compared to a DNA 
standard curve created from lambda DNA. Sample fluorescence was measured using a Promega 
GloMax® plate reader (Promega Corp., Madison, WI. USA).  The standard dilution series generated 
a linear curve from which the DNA content of each sample was determined.   
Methylated CpG Island Recovery Assay   
On day seven post-differentiation, cells were lysated in RIPA (Sigma Aldrich) buffer and the 
genomic DNA was prepared using a Proteinase K/ hot phenol extraction method followed by 
ethanol precipitation (78).  The concentration, purity and quality of each DNA extract were 
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assessed by with a ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Del. USA).  Samples 
with an A260/A230 ratio less than 1.5 were not included in subsequent analyses.   
  The methylated portions of the genomic DNA from mature adipocytes were isolated using a 
MethylCollector Ultra Kit (Active Motif, Carlsbad, CA) which uses the MIRA assay (76).  In brief, 
genomic DNA was fragmented using Mse I. The fragmentation was visualized using the Agilent 
Bioanalyzer DNA7500 Series II assay.  The DNA was captured with a His tagged MBD2/MBD3L1 
protein complex which binds any methylated DNA. Both methylated and non-methylated DNA was 
captured utilizing the MethylCollector column and buffer system.  Methylated DNA was labeled 
with Cy5 and the non-methylated DNA was labeled with Cy3 using a Dual-Color Labeling kit per 
manufacturer’s directions (Roche Nimblegen, Inc. Madison, WI).  The Cy5 and Cy3 labeled DNA was 
hybridized to a NimbleGen Mouse DNA Methylation 385K RefSeq Promoter array as prescribed in 
the NimbleGen DNA Methylation Analysis Guide (Roche Nimblegen, Inc. Madison, WI).   This array 
was designed using the UCSC Mus musculus Build 8 Reference Sequences database with coverage 
2000 bp upstream and 500 bp downstream of each gene promoter region and covering 19,489 
transcript regions.  The area of genomic DNA with enhanced methylation regions was determined 
using Roche DEVA software.   
Total RNA Extraction  
RNA was isolated from adipocytes at day 7 post-differentiation using Ambion’s ToTALLY RNA 
isolation kit (Ambion, Inc. Austin, TX) as directed.  The concentration, purity and quality of each 
RNA extract were assessed by with a ND-1000 spectrophotometer (NanoDrop Technologies, Inc., 
Del. USA).  Samples with an A260/A230 ratio less than 1.5 were not included in subsequent 




Reverse Transcriptase Polymerase Chain Reaction 
 DNA methyltransferase (Dnmt1), Fatty acid synthase (Fasn), Folate receptor 1 (Folr1), Glucose 
transporter 4 (Glut4), Hormone sensitive lipase (Lipe), Leptin (lep), Methylenetetrahydrofolate 
reductase (Mthfr), Peroxisome proliferation activated receptor gamma (Pparγ) and Pparγ co-
activator receptor alpha (Pgc-1α) were quantified by real-time reverse transcriptase polymerase 
chain reaction (RT-PCR) using a 7300 Real-Time PCR system with TaqMan probes listed in Table 1 
on following page. 
A pooled sample containing all samples at (10 ng/ul) was prepared and serially diluted to 
provide a relative standard curve against which all samples were compared. RNA template was 
added to a reaction mix prepared as directed using TaqMan Core Reagent Kit (Applied Biosystems, 
Foster City, CA, USA). All samples and standards were run on the same plate for each gene analyzed 
allowing for direct calculation of relative quantities.  Standard cycling parameters were followed 
except for an initial hold at 48°C for 30 minutes followed by a hold at 95° for 10 minutes prior to 
the cycling start.   Data was acquired after 15 cycles and the concentration of each sample was 
calculated during linear amplification as compared to the response of the relative standard curve.  
Statistical Analysis of Data 
For triglyceride accumulation, lipolysis, and RT-PCR each treatment had 4 biological replicates.  
The MIRA assay was performed as a screening procedure, so no statistical analysis was performed.  
Replicate samples were statistically analyzed by 2-way ANOVA with concurrent pair-wise contrasts 





Table 1 Life Technologies/Applied Biosystems TaqMan ® Probe Assays for RT-PCR 
  Gene ID Gene Name TaqMan Probe ID 
Dnmt1 DNA methyltransferase Mm01151065_g1 
Fasn Fatty acid synthase Mm00662319_m1 
Folr1 Folate receptor 1 Mm00433355_m1 
Lep Leptin Mm0043759_m1 
Lipe Hormone sensitive lipase Mm0095359_m1 
Mthfr Methylenetetrahydrofolate reductase Mm0487784_m1 
PGC1α PPARgamma coactivator 1 alpha Mm00447189_g1 
PPARγ Peroxisome proliferation activated receptor gamma Mm00440945_m1 




Please note all results figures can be found at the end of this chapter and additional data tables 
can be found in the Appendix. 
Cellular Proliferation 
Since cells varied in size after treatment, cellular proliferation was measured by DNA content 
using the CyQuant Assay.  The mean DNA quantities are shown in Figure 3 and Table 3(Appendix) 
for each treatment.  Cells differentiated under folate depleted conditions and exposed to decitibine, 
folate depleted or standard folate conditions during maturation had significantly less DNA than 
cells differentiated under standard or high folate conditions exposed to similar treatments post-
differentiation (p<0.05).  Increasing folate levels post-differentiation in these cells helped them to 
recover to proliferation levels similar to those seen in cells differentiated under standard or high 
folate levels.   There were no statistically significant differences in DNA quantity between cells 
differentiated under standard folate levels matured under folate depleted, standard folate or high 
folate conditions.  For cells differentiated under high folate levels, experiencing folate depleted 
conditions caused a significant increase in proliferation as did exposure to SAMe (p<0.05).  
Triglyceride Accumulation 
Triglyceride accumulation is shown in Figure 4 and Table 3 (Appendix).  Despite having lower 
cell numbers, the cells differentiated under folate depleted conditions exposed to folate depleted 
conditions during maturation accumulated ~30% more than cells differentiated under standard or 
high folate conditions with similar post-differentiation treatments (p<0.005).  Exposure to 
decitibine during the post-differentiation period enhanced triglyceride accumulation in folate 
depleted cells. Conversely, cells differentiated under high folate conditions, then matured under 
folate depleted conditions acquired 40% less triglyceride than those differentiated under folate 
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depleted conditions (p<0.005) and 14% less than those differentiated under standard conditions 
(p<0.005). As previously shown, high folate conditions during differentiation induced cellular 
proliferation, but this was not accompanied by an increase in lipid accumulation if cells were 
exposed to folate depleted or standard levels of folate during the maturation period.  However, 
increasing folate levels during maturation modestly, but significantly, increased lipid accumulation 
in high folate differentiated cells (p<0.05).  
Lipolysis 
In general, the level of lipolysis for each of the treatments reflected the amount of triglyceride 
stores available for release as shown in Figure 5 and Table 3 (Appendix). Furthermore, lipolysis 
decreased in a dose dependent manner with the level of folate exposure during differentiation, i.e. 
folate depleted cells had two to three times the level of lipolysis compared to standard or high 
folate differentiated cells.  Exposure to high folate conditions during differentiation blunted 
lipolysis by up to 50% relative to standard conditions (p<0.05). Surprisingly, exposure to decitibine 
or SAMe during the maturation phase significantly increased lipolysis in the cells differentiated 
under standard or high folate conditions (p<0.0%).  Increasing folate during maturation, decreased 
the level of lipolysis an average of 55% in folate depleted differentiated cells (p<0.05), 27% in 
standard differentiated cells and 18% in high folate differentiated cells.  
Overall Adipocyte Phenotype 
Adipocytes were imaged using an Oil Red O stain 7 days post-differentiation as shown in Figure 
6.  This time-point was selected to capture adipocytes at a non-static point in lipid filling (data not 
shown). Cells differentiated under folate deplete conditions were much smaller and fewer in 
numbers than cells grown under standard or high folate conditions. Addition of folate during the 
post-differentiation period increased cell numbers to levels exceeding that seen in fat cells 
differentiated under standard or high folate conditions (hyperplasia). Folate depleted fat cells 
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acquired more lipid per cell than did fat cells grown under standard or high folate conditions.  In 
addition, these cells released a greater amount of lipid stores under non-stimulated lipolysis.   
Adipocytes differentiated and matured under high folate conditions were more numerous, but did 
not retain as much lipid per cell.  These cells also yielded less lipid release during non-stimulated 
lipolysis.  Treatment with Decitibine created fewer fat cells relative to standard conditions. But 
these cells acquired statistically more triglycerides than cells grown under standard folate or high 
folate conditions.   Cells differentiated under high folate were more numerous and slightly larger 
than cells differentiated under standard or folate depleted conditions.  Despite this fact, the cells 
stored less triglyceride on a per cell basis and as a result released less lipid during non-stimulated 
lipolysis.  
DNA CpG Methylation 
Analysis was performed on cells differentiated under standard folate conditions then exposed 
to folate depleted, standard folate, decitibine or SAMe during the maturation period. As expected 
for CpG Island methylation was decreased globally in the folate depleted and decitibine treated cells 
relative to standard conditions as seen in Figures 7 a through 7 g.   The track on the top shows the 
CpG islands highlighted in red.  Below that track is the transcription start site track which contains 
one or two blue dots representing the site.  Next, is the primary transcript track highlighting the 
entire length of the transcript. The treatment tracks for 2DC, standard folate, SAMe and low folate 
follow with dots representing the level of methylation at each CpG residue.  Dots above the line 
represent hypermethylation and dots below the line infer hypomethylation. Adipocytes grown 
under standard conditions showed the most variability in their CpG methylation track lines. While 
those matured under 2DC and low folate had the most repressed methylation levels. Quite 
unexpectedly, methylation decreased on a global level in the cells given SAMe.  However, some 
specific CpG sites had increased methylation relative to the standard conditions which could affect 




As shown in Figure 8 a, DNA methyltransferase 1 levels did not change significantly in cells 
exposed to decitibine, folate depleted or standard folate conditions during maturation irrespective 
of differentiation conditions.  For cells exposed to high folate or supraphysiological levels of folate 
during maturation, the amount of Dnmt1 mRNA decreased with folate exposure during the 
differentiation condition.  Cells differentiated under folate depleted conditions in general had 
increased levels for Dnmt1 as folate levels increased during the maturation phase whereas cells 
differentiated under high folate decreased the level of Dnmt1 transcripts as folate levels increased 
during the maturation phase.   For cells differentiated under standard conditions, the level of 
Dnmt1 tended to stay constant with folate exposure except in the supraphysiological folate 
treatment group which was significantly higher (p<0.05).  Interestingly, SAMe exposure 
significantly increased Dnmt1 in the folate depleted and standard folate differentiation groups, but 
not in the high folate differentiated group (p<0.05).  Decitibine treatment yielded Dnmt1 levels 
similar to that seen in folate depleted treatments for all differentiation groups.  
High folate levels during differentiation resulted in increased fatty acid synthase transcripts 
relative to cells differentiated under folate depleted or standard folate levels for those matured 
under folate depleted or standard folate levels (p<0.05) as seen in Figure 8b.  Conversely, for cells 
differentiated under high folate levels, Fasn levels decreased in cells exposed to supraphysiological 
folate or SAMe during the post-differentiation period  relative to similar treatments in the folate 
depleted differentiation cells (p<0.05).  For cells differentiated under folate depleted conditions, 
increasing folate levels post-differentiation resulted in increased Fasn expression (p<0.05).  A 
similar trend was seen in those cells differentiated under standard folate conditions (p<0.05), but 
not in high folate conditions.   
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Folate receptor 1 (folr1) levels were significantly higher in cells exposed to decitibine during 
the maturation period (p<0.05), but did not significantly differ with respect to folate exposure 
during the differentiation period as shown in Figure 8c.   For cells differentiated under standard or 
high folate levels, no significant difference was shown in post-differentiation treatments except in 
the decitibine group which was three fold up-regulated (p<0.05). Cells differentiated under folate 
depleted conditions showed a two fold increase in folr1 expression under folate depleted 
conditions during the post-differentiation period (p<0.05).  In general, SAMe treatments had folr1 
levels similar to those seen in the folate depleted maturation groups irrespective of folate 
differentiation levels.   
Expression of glucose transporter 4 seem to be tightly controlled as gene expression levels did 
not vary much with folate exposure either during differentiation or post-differentiation with the 
following exceptions as seen in Figure 8d.  Cells differentiated and matured under folate depleted 
conditions had 60%, 58% and 38% less Glut4 expression than cells differentiated under folate 
depleted conditions and matured under supraphysiological, high folate and standard folate 
conditions respectively,  (p<0.05).   Glut4 expression in cells differentiated under folate deplete 
conditions, but matured under supraphysiological and high folate was significantly higher than in 
cells differentiated under standard or high folate (p<0.05). 
Cells differentiated under folate depleted conditions had significantly lower levels of hormone 
sensitive lipase (lipe) when exposed to folate depleted conditions during the post-differentiation 
period (p<0.05)as shown in Figure 8e. Cells differentiated under standard folate conditions had 
significantly lower levels of hormone sensitive lipase when exposed to high or supraphysiological 
levels of folate during the maturation period (p<0.05). 
    Leptin results showed high variability, but in general the level of folate given during 
differentiation did not significantly change the leptin levels as shown in Figure 8f. However cells 
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exposed to folate depleted conditions post-differentiation tended to have lower levels of lep 
expression (p<0.05). Decitibine treatment after differentiation significantly increased lep levels 
particularly in those cells differentiated under folate depleted conditions (p<0.05) and in cells 
differentiated under standard folate conditions (p<0.05), but not in cells differentiated under high 
folate conditions. 
Methylenetetrahydrofolate reductase levels were constant for cells differentiated under 
standard folate conditions regardless of post-differentiation treatment as seen in Figure 8g.  
Exposure to high folate during the differentiation period significantly increased Mthfr transcript 
levels for all cells given folate depleted, standard folate, or high folate media during maturation 
(p<0.05).  Cells differentiated under folate depleted conditions given high or supraphysiological 
levels of folate during maturation had significantly higher levels of Mthfr (p<0.05). However, in cells 
exposed to folate depleted conditions during differentiation, exposure to either decitibine or SAMe 
during maturation did not significantly increase Mthfr levels.  Cells exposed to high folate during 
differentiation had significantly higher levels of Mthfr when exposed to folate depleted conditions 
during maturation (p<0.05), while exposure to supraphysiological levels of folate during 
maturation, significantly decreased Mthfr in this differentiation group (p<0.05).  
Peroxisome proliferation activated receptor γ (PPARγ) levels increased in the group 
differentiated under high folate conditions for all folate treatments during the maturation period 
relative to those differentiated under folate depleted or standard folate conditions except for 
decitibine and SAMe treatment where the PPARγ levels decreased as seen in Figure 8h. The level of 
PPARγ mirrored the level of proliferation in the cells. Conversely exposure to decitibine or SAMe 
significantly increased PPARγ in cells differentiated under folate depleted and standard folate 
conditions, but not in cells differentiated under high folate conditions (p<0.05).  
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Pgc1α results were highly variable, but the mRNA levels significantly decreased in cells 
differentiated under folate depleted or standard folate conditions, exposed to folate depleted media 
during maturation (p<0.05) as shown in Figure 8i.   Restoring folate to high or supraphysiological 
levels during maturation caused  increased Pgc1α expression in cells differentiated under folate 
depleted conditions (p<0.05).  
Discussion 
We sought to determine how folate exposure during the differentiation and maturation process 
of adipocytes would affect adipocyte number and size as well as lipid storage and release.  Exposing 
adipocytes to very low levels of folate prior to differentiation caused a reduction in cell numbers as 
measured by DNA while increasing folate during differentiation had the opposite effect.  
Conversely, exposing preadipocytes to high levels of folate prior to differentiation, followed by 
exposure to low levels of folate during maturation, caused hyperproliferation of cells.  Yet, despite 
the reduction in cell number, the folate deficient adipocytes stored more triglycerides in each cell 
and became larger in size, while those exposed to high folate during differentiation and low folate 
during maturation stored less lipid per cell.    
Lipolysis levels were closely linked to the triglyceride stores accumulated in the cells.  
Consequently, adipocytes exposed to folate depleted conditions during differentiation and 
maturation had the highest levels of triglycerides stored and highest amount of lipids released. 
Adipocytes given high levels of folate during differentiation and low levels of folate during 
maturation had smaller lipid stores and thus fewer lipids released.   
Peroxisome proliferation activated receptor gamma (PPARγ) is a member of the nuclear 
receptor family and is activated by anti-diabetic drugs such as thiazolidinediones (TZDs).  PPARγ 
can stimulate adipocyte differentiation and PPARγ heterozygous mice have been shown to have 
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smaller adipocytes and less fat along with insulin resistance (79).  Familial Partial Lipodystrophy 
(LPL) has been linked in humans to heterozygous mis-sense mutations in the PPARγ gene.  LPL 
patients have variable levels of insulin resistance including diabetes, hypertension and 
hypertriglyceridemia (80).   Our RT-PCR results showed less PPARγ gene expression in the 
adipocytes differentiated under low folate conditions and matured under low folate conditions, 
while increasing folate during the maturation period caused an increase in PPARγ. Exposure to high 
folate levels during differentiation greatly increased expression of PPARγ even in cells given low 
folate levels during the maturation period.  Surprisingly, exposure to 5-aza-2-deoxycitidine after 
high folate differentiation greatly suppressed PPARγ expression.    
Kang et al found the proximal CpG sites of long CpG islands in human adipocytes were 
consistently unmethylated. However, they also found transitional CpGs were differentially 
methylated in PPARγ (81).  We utilized the microarray based MIRA assay to look at methylation in 
these transitional CpGs not associated with a CpG Island.  In adipocytes exposed to standard folate 
conditions during differentiation, but matured under folate deplete conditions, standard folate, high 
folate or exposed to 5-aza-2 deoxycitidine, we found PPARγ gene expression was nearly similar for 
all maturation conditions except for the 5-aza-2 deoxycitidine treatment which increased PPARγ 
expression nearly 3 fold.  In comparing the MIRA tracks, we can see that while the folate deplete, 
standard folate, high folate CpGs are mostly unmethylated, there are a few methylated CpGs, 
whereas for the 5-aza-2DC track no CpG sites were methylated (Figure 3 g). 
Researchers at the Karolinska Institute recently demonstrated that no effect on lipolysis rate 
was observed when lipolysis was expressed per lipid weight of cell, but when lipolysis was 
expressed per number of fat cells, lipolysis was significantly higher in large adipocytes when 
compared to small adipocytes (69).    They attributed this effect in part to increased protein 
expression of hormone-sensitive lipase, adipose triglyceride lipase and perilipin in the large 
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adipocytes (82). They proposed that enhanced lipolytic capacity may link adipocyte hypertrophy to 
the risk of developing Type 2 diabetes.  In our study, cells differentiated under folate depleted 
conditions were significantly fewer in number when matured under folate depleted conditions.  
Despite being fewer in number, these cells appeared to be larger in size (see Figure 2).  They 
acquired greater triglyceride stores and had more lipids released during lipolysis.  These cells had 
less fatty acid synthase, glucose transporter 4, hormone sensitive lipase, leptin, Mthfr, PPARg, and 
PGC1-α gene expression than cells differentiated under folate depleted conditions which received 
standard, high or supraphysiological folate during maturation.  Folate receptor 1 and Dnmt1 were 
elevated in cells differentiated under folate depleted conditions.  Folate depletion during 
differentiation was shown to globally reduce methylation in the promoter regions of these genes, 
but several methylation sites were maintained.  The up-regulation of the folate receptor and Dnmt1 
may be a compensatory mechanism for these cells to maintain methylation sites. 
While the majority of lipids stored in adipocytes come from dietary intake, these cells can also 
utilize carbohydrates in de novo lipogenesis.  Because of the high energy cost associated with de 
novo lipogenesis, it has been thought to be a minor component in energy balance equations.   Fatty 
acid synthase is responsible for catalyzing the conversion of acetyl Co-A and Malonyl Co A to 
palmitate and has been used as a marker of   de novo lipogenesis.  In our system, FAS was up-
regulated in adipocytes differentiated under folate depleted conditions then exposed to high folate 
conditions during maturation.  Glut4 expression was similarly up-regulated under these conditions.  
Coupled with the triglyceride accumulation data this is evidence that de novo lipogenesis may play a 
major role in lipid accumulation in these cells.   Adipocytes differentiated under high folate 
conditions exposed to high folate during maturation also had elevated FAS levels, but this was not 
concurrent with elevated Glut4 expression or increased triglyceride accumulation.  Under these 
circumstances, de novo lipogenesis may not play a major role in lipid accretion.    
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It has been proposed that methylation sensitive transcription factors contribute to Glut4 gene 
regulation (17). It has been shown that the Glut4 promoter has two highly methylated CpG sites in 
preadipocytes which become demethylated in adipocytes.  Three other CpG sites are demethylated 
in both the preadipocytes and adipocytes.  In our system, under standard conditions, the fully 
mature adipocytes, had slight methylation at 2 CpG sites that was maintained when cells were 
matured under folate depleted or SAMe, but not 2-DC.  However, the level of Glut 4 gene expression 
did not statistically change under any maturation exposures.   
Spalding et al found leptin deficiency in obese persons despite them having increased adipocyte 
numbers (66). Leptin deficiency can increase appetite and lower energy expenditure.  In our 
system, adipocytes matured under high folate conditions, then exposed to folate depleted 
conditions during maturation had leptin levels approximately 1/3 the amount seen in adipocytes 
differentiated under standard or folate depleted conditions despite having more cells numbers.    
The leptin gene is methylated in preadipocytes, but becomes hypomethylated during 
adipogenesis(83).  We found under standard folate differentiation conditions slight 
hypomethylation in a few CpGs, but hypermethylation on the more proximal end.   Exposure to 
folate depleted conditions during maturation, blunted this affect, while SAMe exposure increased 
methylation.   Leptin expression did not seem to correlate with the amount of CpG methylation.  
PPAR γ co-activator receptor 1-alpha (PGC-1α) is a master regulator of mitochondrial functions, 
glucose and fat oxidation and gluconeogenesis. Maternal pregestational BMI has been shown to be 
associated with the level of methylation in the promoter region of PGC-1α in newborns (84). 
Hypermethylation of PGC-1α promoter in non-CpG islands along with reduced mitochondrial 
content has been found in Type 2 diabetic patients (85).  We found adipocytes differentiated and 
matured under folate depleted conditions had 69% less PGC-1α gene expression than did 
adipocytes differentiated under standard conditions.  Exposure to high folate conditions during 
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maturation rescued folate depleted differentiated adipocytes to normal levels of PGC-1α gene 
expression.  This could indicate the potential for impaired mitochondrial function as well as faulty 
glucose and fat oxidation in folate depleted fat cells.  Adipocytes differentiated and matured under 
standard conditions had a wide range of methylated and demethylated CpGs.  Exposure to folate 
depleted conditions during maturation reduced both methylation and demethylation levels and 
could be responsible for limiting transcription factor binding to the promoter site as PGC-1α was 
reduced by a third in these cells.  
Not surprisingly, the folate receptor 1 was up-regulated two-fold in the folate depleted 
conditions and five-fold up-regulated in the 5-aza-2DC treatments.  Of some surprise was the up-
regulation of the folate receptor 1 in the SAMe treatments in cells differentiated under folate 
depleted conditions, suggesting that despite supplementation during the maturation period with 
the end methyl donor, cells still sensed a need for folate.  Folate one-carbon metabolism has been 
shown to localize into cytoplasmic and organelle spaces, but a mechanism for active transport into 
the nucleus has not been found.  It has been suggested that all forms of folate may be taken up into 
the nucleus during cellular replication after dissolution and reformation of the nucleus (86). 
Mitochondrial carriers for SAMe have been found, but not specific membrane carriers (87).  Since 
SAMe was added exogenously to the cells it might not have been transported into the nucleus 
preventing the methylation of DNA. .  This would explain how the adipocytes differentiated under 
standard conditions, yet matured under SAMe would have decreased methylation as shown by the 
MIRA assay. Dnmt1 mRNA was up-regulated 2-fold in SAMe matured cells under the standard 
differentiation conditions this could be a compensatory mechanism.   The level of MTHFR gene 
transcription did not significantly change for cells differentiated under standard folate conditions, 
but it did marginally increase for cells differentiated under folate depleted conditions then matured 




Data from this study suggest the potential early developmental importance of obtaining 
sufficient folate levels for the prevention of obesity by highlighting the potential problems that may 
result from a disparity between folate levels during the differentiation period versus folate levels 
during the maturation period.    Exposure to folate deficient environments during early adipocyte 
development appears to greatly reduce adipocyte numbers yet increase lipid accumulation.  
Increasing folate during the maturation period serves to increase the adipocyte numbers, but not 
the amount of lipid stored. Therefore, once differentiation has occurred, one cannot ameliorate the 
problem of low lipid storage caused by either inadequate fat cell numbers or lipid accretion in cells 
differentiated under folate depleted conditions.  The marked increase in lipolysis  per cell number 
under folate deficient conditions demonstrates that these cells can rapidly release their lipids and is 
likely a function of the expanded lipid stores in these cells however this could exacerbate the 
problem of lipid spillover into plasma in whole systems(88).  Finally, markers of de novo lipogenesis 
seems to be stimulated in the adipocytes differentiated under folate depleted conditions when 
compared to those exposed to high folate during maturation.  Adipocyte differentiated under high 
folate conditions and subsequently matured under folate depleted conditions had drastically 
reduced levels of leptin gene expression which, if translated into protein levels, could be 
responsible for dysregulation of appetites in whole systems. Although the majority of adipogenesis 
occurs during early development, an estimated 10% of adipocytes die and are replaced each year 
from a pre-adipocyte pool (66), thus providing an opportunity to impact metabolism through 
providing optimal folate levels during differentiation and maturation throughout life.   
The MIRA assay allowed us to look at global methylation events without the biases occurred 
from bis-sulfate conversion, PCR amplification and sequencing.  We were able to detect increases in 
global hypomethylation under folate limiting conditions in cells that were differentiated under 
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standard folate conditions indicating that de novo methylation events occur in cells post-
differentiation.  However, we were not able to assess the folate depleted differentiation treatments 
versus the high folate differentiation treatments using the MIRA assay.  The addition of the master 
methyl donor s-adenosylmethionine surprisingly did not increase DNA methylation perhaps in part 
to the inability of the SAMe to be transported into the nucleus.  Another limitation of the study is we 
measured markers of de novo lipogenesis but did not directly measure lipogenesis.  However, to our 
knowledge, this is the first in-vitro study to look at the effects of limiting folate during 
differentiation and maturation of adipocytes.   
It is clear that exposure to folate deficiency during differentiation of adipocytes has lasting 
ramifications on total number of fat cells and the size of fat cells.  These cells become programmed 
to store more triglyceride per cell than fat cells differentiated under standard or high folate 
conditions.  If one considers a whole body system composed of fat cells with this phenotype 
exposed to a high fat diet, the system would have limited capacity to store excess lipid.  
Furthermore, these cells exhibit an increased lipolytic capacity, meaning they rapidly release stored 
lipid.  This could lead to dsylepidemia.  Exposing cells differentiated under low folate to high folate 
during maturation, increased the cell numbers, but not the size.  The result would be more storage 
capacity for a whole system.  Conversely, adipocytes differentiated under high folate conditions, 
then matured under low folate conditions exhibited increased lipolysis perhaps by increased gene 
expression of hormone sensitive lipase and signs of de novo lipogenesis. These cells also had 
increased leptin expression despite having fewer cell numbers in culture.  In light of this research, 
future studies on obesity, dyslipidemia and T2D would do well to incorporate folate status and 




Figure 3 DNA estimates graphical and tabular views for mean and standard deviations (n=4)  
Data can be found in the appendix. 1. Non-matching letter superscripts in each row denote significant difference (p<0.05) 2. Non-matching 




Figure 4 Triglyceride accumulation graphical and tabular views for mean and standard deviations (n=4) 
 Data can be found in the appendix. 1. Non-matching letter superscripts in each row denote significant difference (p<0.05) 2. Non-




Figure 5  Lipid release graphical and tabular views for mean and standard deviations (n=4)  
Data can be found in the appendix 1. Non-matching letter superscripts in each row denote significant difference (p<0.05) 2. Non-












































Figure 8 a. DNA Methyltransferase 1 gene expression levels as measured by RT-PCR  The table below the graph contains the average 
with standard deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter 





Figure 8 b. Fatty acid synthase gene expression levels as measured by RT-PCR.  The table below the graph contains the average with 
standard deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter 
superscripts in each row denote significant difference (p<0.05) 2. Non-matching numerical superscripts in each column denote significant 




Figure 8 c. Folate receptor 1 gene expression levels as measured by RT-PCR The table below the graph contains the average with 
standard deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter 





Figure 8 d. Glucose transporter 4 gene expression levels as measured by RT-PCR  The table below the graph contains the average with 
standard deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter 





Figure 8 e. Hormone sensitive lipase gene expression levels as measured by RT-PCR  The table below the graph contains the average 
with standard deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter 





  Figure 8 f. Leptin gene expression levels as measured by RT-PCR  The table below the graph contains the average with standard 
deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter superscripts in 





Figure 8 g. Mthfr gene expression levels as measured by RT-PCR  The table below the graph contains the average with standard 
deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter superscripts in 





Figure 8 h. Pparγ gene expression levels as measured by RT-PCR  The table below the graph contains the average with standard 
deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter superscripts in 





Figure 8 i. Pgc-1α gene expression levels as measured by RT-PCR  The table below the graph contains the average with standard 
deviation and the data can be found in the appendix.  Statistical analysis by 2-way ANOVA (n=4).  1. Non-matching letter superscripts in 




Chapter 4 Conclusions 
Studies on adipocyte metabolism in vitro have been based on standard folate concentrations 
during differentiation from pre-adipocytes to mature adipocytes.  In whole body systems, folate 
concentrations are often lacking or suboptimal during differentiation and maturation.  
Alternatively, excessive folate may be encountered during initial development of the fat cell.  The 
level of folate obtained during the maturation phase of the fat cell may be very high, merely 
adequate or lacking.  This research was designed to study the effect of varying folate levels on the 
adipocyte metabolism.  By altering the levels of folate given during the differentiation period and 
the maturation period, we found that the amount given to the cell during the differentiation period 
was more significant than that given during the maturation period.  That is to say the amount of 
folate “sensed” during differentiation played a greater role in determining the adipocyte phenotype 
than did the amount of folate “sensed” during the maturation period.  By comparing four conditions 
relevant to the standard condition, we can find trends, as shown in Table 2, that may relate to 
adipocyte cell types we see in vitro. 
First let us look at the comparison between adipocytes differentiated and matured under low 
folate conditions versus those grown under standard conditions.   First the low folate condition 
produces far less fat cells than does the standard media conditions and the cells are smaller in size.  
This is not surprising considering folate is necessary for manufacturing DNA building blocks.   We 
see a down regulation of many genes including PPARγ, PGC-1a, Glut4 and Fasn.    The decrease seen 
in the adipogenesis marker PPARγ further supports the reduction in cell number.  A very large 
decrease in Pgc1-α predicts that these cells may have less capacity to generate mitochondria.   
Down regulation of two markers of de novo lipogenesis, Fasn and Glut4 may indicate that this mode 
of triglyceride production is limited.  A visual inspection of the cells by Oil Red O staining reveals 
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that although there are fewer cells present, each is packed full of lipid.  Because each cell has 
acquired a massive store of triglyceride, there is a 2 fold increase in the amount of lipid released 
during unstimulated lipolysis.   We see an up-regulation of Folr1, which indicates these cells are 
trying to scavenge any folate possible.  Low folate during differentiation and maturation would 
create a situation of few, small fat cells that scavenge any triglyceride available, but would also 
readily release these energy stores when needed.   When this fat cell type encounters a high fat diet, 
the fat cells would take up as much fat as possible, but due to their limited numbers, the system 
would not have much capacity for storage.  If the high fat diet was continued the system would be 
forced to find alternative places for fat storage, such as muscle and other organs creating a 
dyslipidemic situation.  
Next, we will consider adipocytes differentiated under low folate conditions, then matured 
under high folate conditions.  Increasing folate during the maturation level yields a higher number 
of cells, but they are still smaller in size than those grown under standard conditions, a situation of 
hyperplasia without hypertrophy.   These cells had a 2 fold increase in expression of PPARγ, which 
concurs with the increased cell numbers.  The cells also had an increase in Fasn gene expression 
relative to standard conditions and they stored more triglyceride on a per cell basis.  However, 
these fat cells had less un-stimulated lipolysis than did the cells grown under standard condition 
despite having more numbers and more triglyceride stored.    These cells had increased expression 
of the Folr1 indicating a continued drive by these cells to sequester folate.   If we challenged these 
cells with a high fat diet, how would they handle it?  We propose that given the greater cell 
numbers, these cells would be better equipped to store excess lipid than cells differentiated and 
matured under folate depleted conditions.  However, their ability to release triglycerides for energy 
when needed is reduced as compared to cells grown under standard conditions.   
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Adipocytes differentiated under high folate conditions, then matured under low folate had 
fewer cell numbers than adipocytes grown under standard conditions.  These cells had a 2 fold 
increase in lipolysis on a per cell basis.  Unlike cells differentiated and matured under total folate 
depleted conditions, cells differentiated under high folate conditions had increased Fasn gene 
expression.  They also had an increase in hormone sensitive lipase gene expression which may play 
a role in the increase in lipolysis.  These cells had an increase in Mthfr which may be a 
compensatory mechanism for the low folate situation seen during maturation in cells programmed 
under high folate conditions.   Surprisingly, these cells had a two fold increase in leptin gene 
expression, despite having fewer cell numbers than standard growth conditions.   This could 
indicate a situation where the adipocytes are signaling to the whole body that the environment is 
high in nutrients, despite being low in nutrients.   
Finally, we will consider adipocytes differentiated and matured under high folate conditions.  
There was no statistically significant change in cell numbers under this condition; however, the 
cells were visually larger than cells grown under standard conditions (data not shown).  This 
indicates a situation of hypertrophy without hyperplasia.  These cells had a 2 fold increase in PPARγ 
gene expression relative to the standard growth conditions.  Despite being larger in size these cells 
did not have more triglyceride stores.  We harvested and tested the cells after 7 days to acquire 
data during a non-static period.  When visualizing these cells with Oil Red O lipid stain, one could 
see the lipid partitioning to the outer edges of the cells, leaving a void in the center presumable that 
could be filled if given enough time.  These cells also had down regulation of the Glut4 gene relative 
to the standard conditions.  If challenged by a high fat diet, how would these cells react?  We 
propose they would have sufficient cellular volume to handle the excess lipid stores.   
The amount of folate available to adipocytes directly affects the ability of these cells to maintain 
DNA methylation.  While folate exposure during initial stages of differentiation has sustained effects 
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on transcription of genes involved in lipogenesis, lipolysis and metabolism, folate concentration 
seen by the cell during later stages also affect rates.  In total, the differences in folate concentration 
experienced between the two stages ultimately determines the size, lipid content and rate of lipid 
release.  Normally, experiments in adipocytes are carried out in cells exposed to standard folate 
conditions both during the initial and later stages of differentiation.  The literature base contains 
papers largely written under these conditions.  Some genes such as hormone sensitive lipase and 
fatty acid synthase are not highly expressed under these conditions in adipocytes.   But in cells 
exposed to low folate during the initial stages of differentiation, these two genes are highly up-
regulated. Furthermore, the gene expression level of HSL increased as the amount of folate 
increased during the maturation process.  HSL is known to be stimulated by catecholamines 
perhaps through a cAMP dependent protein kinase (89). Oral folic acid supplementation was shown 
to increase the effects induced by beta adrenergic receptor activation in diabetic/obese mice(61).  
Although the authors of the study did not investigate the mechanism by which folic acid sensitized 
the cAMP-PKA dependent pathway, they hypothesize that folic acid supplementation may prevent 
PKA inactivation or enhance the phosphorylation of hormone sensitive lipase by PKA.  Our results 
suggest that folic acid supplementation may directly affect the expression of the hormone sensitive 
lipase gene by modulating the methylation pattern of the CpGs and affect transcription factor 
binding.  
Development from a single egg into hundreds of different cell types is initiated by global 
demethylation followed by methylation.  DNA methyltransferases faithfully transcribe methylation 
marks onto daughter cells.  Cellular differentiation of stem cells involves not only DNA 
demethylation, but also methylation of multiple genome wide loci.    This process is not restricted to 
early embryo development, but also occurs in differentiation of somatic tissues. Not all DNA 
methylation changes which occur during differentiation are epigenetically inherited.  DNA 
methylation during differentiation may temporally regulate gene transcription during the 
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differentiation process.  For example, the promoter regions of Lep and Glut4 are methylated during 
early adipocyte differentiation, but become hypomethylated during later stages of 
differentiation(83),(17).  Even the upstream region of Dnmt1 is differentially methylated during the 
specific developmental stages (90).  Differentiation of 3T3L1s adipocytes is associated with 
genome-wide epigenetic changes, and the status of methylation and demethylation is maintained or 
changed depending on the stage of differentiation and genomic loci (70).  DNA methylation changes 
are not only unidirectional methylation/demethylation events, but also transient, indicating that 
the epigenetic change is dynamic rather than static.    
Our research shows that the DNA methylation marks are not only an indication of origin, but 
also a product of nutritional status during the time of differentiation and as well as maturation of 
the cell.  Furthermore, folate availability modulates DNA methylation marks via the one carbon 
cycle and SAMe production.  Having sufficient folate levels during adipocyte differentiation is 
critical to the development of sufficient numbers of adipocytes capable of properly storing and 
releasing triglycerides and for proper hormonal signaling.  Future studies of obesity should include 
monitoring epigenetics of adipocytes to better define their phenotype and metabolic capacity in 





Table2 Adipocyte response relative to adipocytes differentiated and matured under standard 









Fewer Cell numbers Greater Cell Numbers 




Greatly Decreased Pgc1α 
gene expression 
2x more PPARγ gene 
expression 
Decreased Glut4 gene 
expression 
More Triglyceride Stored per 
cell 
Decreased Fasn gene 
expression 
Increased Fasn gene 
expression 
2x more lipolysis per cell Less Lipolysis per cell 
Increased Folr1 gene 
expression 




Fewer Cell numbers No change in Cell Numbers 




Increased Fasn gene 
expression 
2x more PPARγ gene 
expression 
2x more lipolysis per cell Less Lipolysis per cell 
Increased Lipe gene 
expression 
Decrease in Glut4 gene 
expression 
Increase Mthfr gene 
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Table 3 DNA, triglyceride and lipolysis estimates, mean ± standard deviation (n=4 per group)  
1. Non-matching letter superscripts in each row denote significant difference (p<0.05) 2. Non-
matching numerical superscripts in each column denote significant difference (p<0.05) 
 
  
 Differentiation Conditions 





Treatment DNA (mM)  
Decitabine 4.10 ± 0.70 a,1 5.96 ± 0.37 b,1 6.05 ± 0.23 b,1 
Folate Depleted 4.89 ± 0.68 a,1 7.88 ± 1.15 b,1 8.25 ± 0.65 b,2 
Standard Folate 4.76 ± 0.41 a,1 6.22 ± 0.25 b,1 6.78 ± 0.66 b,1 
High Folate 4.78 ± 0.48 a,1 5.68 ± 0.83 a,1 5.63 ± 0.79 a,1 
Supraphysiological 
Folate 
6.31 ± 1.15 a,1 6.46 ± 0.77 a,1 6.72 ± 0.66 a,1 
S-adenosylmethionine 6.23 ± 0.55 a,2 6.73 ± 0.21 a,1 7.37 ± 1.40 a,2 
 Triglyceride (ORO Density/mM DNA) 
Decitabine 0.32 ± 0.08 a,1 0.19 ± 0.03 b,1 0.18 ± 0.01 b,1 
Folate Depleted 0.20 ± 0.04 a,2 0.14 ± 0.03 b,2 0.12 ± 0.02 b,2 
Standard Folate 0.20 ± 0.03 a,2 0.17 ± 0.01 a,1 0.16 ± 0.02 a,1 
High Folate 0.21 ± 0.03 a,2 0.18 ± 0.03 a,1 0.20 ± 0.05 a,1 
Supraphysiological 
Folate 
0.15 ± 0.03 a,2 0.16 ± 0.01 a,1 0.17 ± 0.03 a,1 
S-adenosylmethionine 0.18 ± 0.01 a,2 0.17 ± 0.02 a,1 0.16 ± 0.05 a,1 
 Lipolysis (mM glycerol/mM DNA) 
Decitabine 0.064 ± 0.002 a,1 0.035 ± 0.003 b,1 0.029 ± 0.003 b,1 
Folate Depleted 0.056 ± 0.011 a,1 0.023 ± 0.004 b,2 0.013 ± 0.002 c,2 
Standard Folate 0.032 ± 0.008 a,2 0.017 ± 0.003 b,2 0.009 ± 0.001 c,2 
High Folate 0.043 ± 0.007 a,2 0.020 ± 0.004 b,2 0.010 ± 0.002 c,2 
Supraphysiological 
Folate 
0.034 ± 0.005 a,2 0.017 ± 0.002 b,2 0.015 ± 0.002 b,2 
S-
adenosylmethionine 
0.060 ± 0.009 a,1 0.033 ± 0.002 b,1 0.025 ± 0.005 c,1 
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Table 4 RT-PCR Results 
1. Non-matching letter superscripts in each row denote significant difference (p<0.05) 2. Non-
matching numerical superscripts in each column denote significant difference (p<0.05) 
 Folate Depleted Standard Folate High Folate 
Post-Differentiation 
Conditions Differentiation Conditions 
 DNA methyltransferase 1 
Decitabine 12.08 ± 2.25a,1 13.98 ±0.63 a,1 14.46 ± 0.28 a,1 
Folate Depleted 11.47± 1.83 a,1 9.97 ± 1.24 a,1,2 14.56 ± 1.63 a,1 
Standard Folate 8.13 ± 0.99 a,1 9.37 ± 1.21 a,2  11.04 ± 0.45 a,1,2 
High Folate 16.85 ± 3.36 a.2 7.99 ± 0.50 b,2 11.03 ± 0.54 b,1,2 
Supraphysiological Folate 14.75 ± 1.23 a,1,2 11.69 ± 0.31 a,b,1 10.43 ± 1.06 b,1,2 
S-Adenosylmethionine 25.18 ± 3.34 a,3 19.35 ± 0.94 b,3 16.40 ± 1.13 b,1 
 Fatty acid synthase 
Decitabine 5.89 ± 1.18 a,1 3.68 ± 0.49 b,1 1.77 ± 0.09 c,1 
Folate Depleted 1.23 ± 0.17 a,2 0.93 ± 0.04 a,2 4.03 ± 0.57 b,2 
Standard Folate 1.94 ± 0.26 a,2 1.80 ± 0.1 a,2 3.67 ± 0.72 b,2 
High Folate 4.76 ± 1.09 a,1 2.39 ± 0.12 a,1 3.37 ± 0.58 a,2 
Supraphysiological Folate 5.53 ± 0.59 a,1 2.94 ± 0.12 b,1 3.51 ± 0.44 b,2 
S-Adenosylmethionine 5.52 ± 0.54 a,1 4.02 ± 0.38 a,b,1 3.03 ± 0.33 b,1 
 Folate receptor 1 
Decitabine 24.24± 2.45 a,1 25.59 ± 6.26 a,1 26.48 ± 2.99 a,1 
Folate Depleted 8.95 ± 1.31 a,2,3 7.48 ± 0.83 a,2 9.44 ±0.75 a,2 
Standard Folate 4.10 ± 1.19 a,3 5.02 ±0.74 a,2 5.22 ± 0.35 a,2 
High Folate 6.8 ± 1.54 a,2,3 4.16 ± 0.64 a,2 4.58 ± 0.30 a,2 
Supraphysiological Folate 4.46 ± 0.62 a,2,3 4.46 ± 0.12 a,2 4.63 ± 0.08 a,2 
S-Adenosylmethionine 9.57 ± 1.00 a,2 8.68 ± 1.11 a,2 9.08 ± 0.71 a,2 
 Glucose transporter, member 4 
Decitabine 3.82 ± 1.26 a,1 3.37 ± 0.71 a,2 1.59 ± 0.29 a,1 
Folate Depleted 1.92 ± 0.42 a,2 2.16 ± 0.48 a,1 1.97 ± 0.14 a,1 
Standard Folate 3.09 ± 0.45 a,1 3.06 ± 0.34 a,2 2.64 ± 0.20 a,1 
High Folate 4.65 ± 1.58 a,1 2.23 ± 0.31 b,1 1.66 ± 0.34 b,1 
Supraphysiological Folate 4.82 ± 0.92 a,1 2.62 ± 0.26 b,1 2.79 ± 0.41 b,1 
S-Adenosylmethionine 4.09 ± 0.95 a,1 4.44 ± 1.17 a,2 3.48 ± 0.63 a,1 
 Hormone sensitive lipase 
Decitabine 9.86 ± 2.26 a,1 8.86 ± 1.04  a,1 6.83 ± 0.52 a,1 
Folate Depleted 6.90 ± 1.32 a,2 7.23 ± 0.30 a,1 7.78 ± 0.09 a,1 
Standard Folate 8.15 ± 1.14 a,1 7.33 ± 0.66 a,1 7.15 ± 0.21 a,1 
High Folate 10.61 ± 2.17a,1 6.94 ± 0.33 b,2 6.64± 0.70 b,1 
Supraphysiological Folate 10.22 ± 0.48 a,1 6.93 ± 0.44 b,2 12.45 ± 3.09 a,2 




Table 4 RT-PCR Results Continued 
  
  
 Folate Depleted Standard Folate High Folate 
Post-Differentiation 
Conditions Differentiation Conditions 
 Leptin 
Decitabine 21.87± 4.64 a,1 21.87± 4.64 a,1 21.87± 4.64 a,1 
Folate Depleted 1.81± 0.47 a,2,3 1.81± 0.47 a,2,3 1.81± 0.47 a,2,3 
Standard Folate 6.64 ±1.78 a,2 6.64 ±1.78 a,2 6.64 ±1.78 a,2 
High Folate 10.03± 3.47 a,2 10.03± 3.47 a,2 10.03± 3.47 a,2 
Supraphysiological Folate 8.75 ± 4.09 a,2 8.75 ± 4.09 a,2 8.75 ± 4.09 a,2 
S-Adenosylmethionine 4.30 ± 1.77 a,2 4.30 ± 1.77 a,2 4.30 ± 1.77 a,2 
 Methylenetetrahydrofolate reductase 
Decitabine 4.84 ± 0.76 a,1 4.84 ± 0.76 a,1 4.84 ± 0.76 a,1 
Folate Depleted 4.79 ± 0.64 a,1 4.79 ± 0.64 a,1 4.79 ± 0.64 a,1 
Standard Folate 6.87 ± 1.40 a,1 6.87 ± 1.40 a,1 6.87 ± 1.40 a,1 
High Folate 8.31 ± 0.73 a,2 8.31 ± 0.73 a,2 8.31 ± 0.73 a,2 
Supraphysiological Folate 7.38 ± 1.20 a,2 7.38 ± 1.20 a,2 7.38 ± 1.20 a,2 
S-Adenosylmethionine 6.13 ± 1.06 a,1 6.13 ± 1.06 a,1 6.13 ± 1.06 a,1 
 Peroxisome proliferation activated receptor γ 
Decitabine 13.62 ± 5.12 a,1 13.62 ± 5.12 a,1 13.62 ± 5.12 a,1 
Folate Depleted 3.66 ± 0.74 a,2 3.66 ± 0.74 a,2 3.66 ± 0.74 a,2 
Standard Folate 6.28 ± 0.92 a,2 6.28 ± 0.92 a,2 6.28 ± 0.92 a,2 
High Folate 8.01 ± 2.30 a,2 8.01 ± 2.30 a,2 8.01 ± 2.30 a,2 
Supraphysiological Folate 8.70 ± 1.81 a,2 8.70 ± 1.81 a,2 8.70 ± 1.81 a,2 
S-Adenosylmethionine 17.26 ± 4.72 a,1 17.26 ± 4.72 a,1 17.26 ± 4.72 a,1 
 Pparγ co-activator receptor 
Decitabine 9.12 ± 2.78 a,1 9.12 ± 2.78 a,1 9.12 ± 2.78 a,1 
Folate Depleted 6.34 ± 1.64 a,1 6.34 ± 1.64 a,1 6.34 ± 1.64 a,1 
Standard Folate 11.24 ± 2.31 a,1 11.24 ± 2.31 a,1 11.24 ± 2.31 a,1 
High Folate 25.81 ± 5.30 a,2,3 25.81 ± 5.30 a,2,3 25.81 ± 5.30 a,2,3 
Supraphysiological Folate 24.98 ± 3.65 a,2,3 24.98 ± 3.65 a,2,3 24.98 ± 3.65 a,2,3 




Julia graduated from the University of TN in 1991 with dual Bachelor of Science degrees in 
Microbiology.  She began working for the Distinguished Scientist, Dr. David C. White at the Institute 
for Applied Microbiology (IAM) performing microbial community analysis using signature lipid 
biomarker (SLB) assays.  Over the next 5 years, Julia attended Hewlett Packard courses in gas 
chromatography and mass spectroscopy to learn theory, maintenance and troubleshooting of these 
instruments and returned to UT for Analytical Chemistry and Physical Biochemistry classes.  During 
her time at IAM, Julia was involved in hundreds of projects and trained visiting scientist from all 
over the globe SLB analysis. 
In 1996 Julia returned to UT in Dr. Gary Saylor’s lab to obtain her Master’s degree in 
Microbiology.  She developed a 16S Ribosomal RNA analysis to identify various microbial 
populations in soil samples utilizing a nylon membrane macroarray approach.  Her work was 
funded by a Westinghouse Fellowship for Novel research. 
After completing her Master’s degree, Julia worked briefly organizing Dr. Steven Wilhelm’s new 
lab at UTK, then at Shaw Engineering’s lab performing environmental assessments for 
bioremediation feasibility studies before taking a post-master’s position at the Oak Ridge National 
Laboratory’s Environmental Sciences Division working with Dr. Jizhong Zhou.  There she became a 
team member developing cDNA microarrays for the Department of Energy’s Whole Genome Project 
for Shewanella onendiensis and Rhodoseudomonas palustrus.  The project involved tracking 
hundreds of samples through primer design, PCR amplification, resultant products, clones and 
sequencing.  For this project, Julia helped in the development of the PRIMEGENS program for high-
throughput primer design and wrote robotic scripts for the MWG Research and Biomek liquid 
handlers as well as the Cartesian Array Printer.  During this time she also learned how to run the 
ABI 3700 capillary sequencer.   
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Dr. David White’s group recruited Julia back to IAM when her post-master’s was finished at 
ORNL.  She took over as lead on an NIH project to study the formation of oral biofilms utilizing 
anaerobic growth chambers and specially designed flow through slides.  The biofilms were imaged 
using a confocal laser microscope system (CLM).  Julia took a year hiatus from academic research to 
tour over 100 other laboratories in Eastern Tennessee as a sales representative for Fisher Scientific.  
This gave Julia access to pharmaceutical, environmental, food and biotechnology labs during which 
time she was exposed to a very wide assortment of various types of equipment and experimental 
assays.   She also learned the business aspect of science, marketing, sales and pricing. 
In January of 2004, Julia was hired to oversee the new Affymetrix Core Lab Facility in the 
Nutrition Department at UTK.  She noted that many of the research projects investigating diseases 
involved similar pathways and particular genes. In 2007, she enrolled in the Comparative and 
Experimental Medicine program to gain greater insight into the potential meaning of the 
microarray results.  Dr. Michael Zemel agreed to serve as a mentor and allow Julia the flexibility 
needed to both continuing her Affymetrix work along with her own research into interactions with 
ones nutritional environment and the genetic basis for metabolic disease states.  After watching a 
NOVA program on Dr. Randy Jirtle’s work, Julia decided to look at the effects of folate on DNA 
methylation in adipocyte development.  
